SAINT LAURENT, Quebec, April 24, 2012 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) (“IntelGenx”) today announced the commencement of a pivotal bioequivalence clinical trial with its anti-migraine VersaFilm product, an oral thin-film formulation of a leading triptan for the treatment of acute migraine. The screening and recruitment of all subjects for the trial has been completed, and first dosing commenced on April 23, 2012.
